Abstract
PURPOSE: We have previously reported that infliximab, a chimeric antibody that binds tumor necrosis factor-alpha (TNF), was useful therapy for patients with refractory sarcoidosis. Etanercept, a TNF receptor antagonist, was not effective for ocular sarcoidosis or chronic uveitis. Infliximab and etanercept are equally effective for rheumatoid arthritis, but only infliximab works for Crohn's disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
